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Introduction 
 
Alzheimer’s disease (AD) is now believed to af-
fect almost 36 million people worldwide and its 
prevalence is estimated to rise to 115.4 million 
by 2050 [1]. One of the key pathological hall-
marks of AD is the accumulation of amyloid-β 
peptide (Aβ) in the extracellular space, the vas-
culature and in neurons [2]. However, vascular 
risk factors, such as hypertension, hypercholes-
terolaemia and diabetes, have also long been 
implicated in the aetiology of AD (for review see 
[3]) and are likely not only to contribute to re-
duced cerebral perfusion, impaired regulation of 
cerebral perfusion and blood-brain barrier (BBB) 
dysfunction but may also increase Aβ produc-
tion and impair its clearance. 
 
In addition to increasing risk for cerebrovascular 
and coronary heart disease, hypertension is a 
risk factor for AD and vascular forms of cogni-
tive decline [4]. Both epidemiological and neuro-
pathological studies have demonstrated a link 
between mid-life hypertension and risk of AD, 
associated with increased accumulation of Aβ 
[5, 6]. Hypertension is often treated by admini-
stration of angiotensin-converting enzyme in-
hibitors (ACE-Is) or angiotensin receptor block-
ers (ARBs) which act to inhibit the production 
and action of angiotensin II (AngII) respectively 
[7]. In addition to reducing the risk of 
atherothrombotic vascular diseases, these 
medications also appear to preserve cognitive 
function by reducing the incidence [8-10] and 
rate of progression of AD [9, 11, 12] and mild 
cognitive impairment [13-17]. This has led to 
the consideration of these drugs as potential 
treatments for AD [18-20]. However, there re-
mains uncertainty as to whether or not all of 
these drugs are protective [17, 21-23] and 
which sub-types are most likely to be helpful in 
AD [12, 17, 23]. 
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The mechanisms of protection against AD is 
unclear; ACE-Is and ARBs are likely to benefit 
people by lowering blood pressure and improv-
ing cerebral blood flow [24]. There is also 
mounting evidence of interactions between 
blood pressure and Aβ pathology such that hy-
pertension exacerbates Aβ accumulation [25-
27]. Conversely, several in vitro, in vivo and ex 
vivo laboratory studies have demonstrated that 
ACE, as a mediator of Ang II formation, itself 
promotes the degradation of Aβ [24, 28-36] and 
according to some animal studies ACE-Is admin-
istered to older animals for prolonged periods 
can exacerbate Aβ pathology [29, 35]. Thus, it is 
possible that some anti-hypertensives improve 
vascular function and perhaps Aβ production in 
the short-term whilst others, ACE-Is in particular, 
may have deleterious effects when adminis-
tered over prolonged periods, due to reduced 
degradation of Aβ and interference with Ang II 
activity (potentially reducing release of acetyl-
choline, altering G-protein signalling, and pro-
moting inflammation [7, 37-42]). The impor-
tance of the non-vascular actions of Ang II are 
supported by several in vivo studies in which 
ARBs improved cognitive performance and di-
minished Aβ pathology in animal models of AD 
[34, 35, 43, 44], and from population based 
studies showing the superiority of ARBs over 
ACE-Is and other antihypertensive drugs in re-
ducing the incidence of AD [8, 9]. 
 
We recently examined whether treatment for 2 
months with ACE-Is or ARBs accelerated the 
initiation of AD-type pathology in La Ferla 
3xTGAD mice. We found no effect of either 
treatment on early AD pathology in mice aged 5-
6 months, with no change in neuronal or total 
oligomeric Aβ [45]. We have now examined 
whether more prolonged (6 month) administra-
tion of an ACE-I (captopril) or an ARB 
(eprosartan) affects the progression of AD-
related pathological changes and cognitive func-
tion in much older (16 month) 3xTGAD mice. 
 
Materials and methods 
 
Animals 
 
Adult (9-10-month old), male triple transgenic 
(3xTGAD: PS1m146vKL; Thy1.2-APPswe; Thy1.2-
tauP301L) mice [46] were used in this study. The 
animals were group housed under a 12-hour 
light-dark cycle with access to food and water 
ad libitum. Room temperature was maintained 
at approximately 21 ± 2°C. Prior to study com-
mencement mice (n=60 in total) were randomly 
assigned to one of three groups: a control un-
treated group (n=22), and two representative 
drug treatment groups for ARBs (eprosartan, 
n=19) and ACE-Is (captopril, n=19). Research-
ers were blinded to drug treatment at all times. 
All animal procedures were performed accord-
ing to the Animal Scientific Procedures Act of 
1986 under license from the United Kingdom 
Home office. 
 
Drug treatment 
 
Drugs were administered in drinking water to 
avoid the stress of repeated injections over a 6-
month period and to mimic the human route of 
administration. Eprosartan was administered at 
0.8g/l, captopril at 2g/l. The control group re-
ceived drinking water only. The doses were in-
formed by previous work [45] and pilot studies. 
The dose of captopril was reduced from 5g/l, as 
used in our previous study [45], to 2g/l to re-
duce the hypotensive effects that we found to 
be mediated by the higher dose in younger ani-
mals [45]. Drugs were prepared as described 
previously [45]. All drinking solutions were 
freshly prepared twice each week, the contain-
ers wrapped in aluminium foil to avoid photo-
chemical changes, and kept at room tempera-
ture to avoid precipitation from solution. Fluid 
consumption was monitored twice weekly 
throughout the study. 
 
Blood pressure measurement 
 
Mean arterial blood pressure (MABP) was moni-
tored non-invasively with a tail sphygmoma-
nometer at baseline, prior to the start of drug 
administration; at 2 weeks and 3 months after 
the commencement of drug administration; and 
2 weeks prior to behavioural testing which was 
undertaken before termination of the experi-
ment (i.e. following 6 months of treatment). Ten 
measurements of MABP were taken each day 
and the average for each mouse determined 
from the last 5 measurements. Mice were ha-
bituated to the procedure for 5 days before 
each measurement day to minimise any con-
founding effects on MABP that could result from 
any stress or anxiety. Visual inspection of the 
sphygmomanometer pulse trace was also car-
ried out to ensure that movement artefacts had 
not occurred during the measurement; if these 
were detected the measurement was discarded. 
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Any measurement that coincided with a heart 
rate of over 700 beats per minute (bpm) was 
discarded as this is indicative of excessive 
stress in the animal [47]. A preliminary analysis 
of the data was conducted to determine if there 
were any differences in baseline blood pressure 
(BP) using 1-way ANOVA with Dunns multiple 
comparisons post-hoc test. Thereafter a 1-way 
repeated measures ANOVA with Newman-Keuls 
multiple comparisons post-hoc test was used to 
assess the affect of each drug upon BP over 
time. 
 
Behaviour 
 
Morris water maze: After 6 months of drug ad-
ministration, short and long-term memory was 
assessed using a validated 2-day water maze 
protocol [48], with minor modifications. Briefly, 
animals were trained to criterion (90% escaping 
under 60 seconds) on a series of visible plat-
form trials on day 1 (D1) in a pool measuring 
2m in diameter and 35cm deep, and monitored 
using Actimetrics Watermaze tracking software. 
The water temperature was 25 ± 1°C. Animals 
were given four visible platform trials (V1-V4) on 
D1 with trials staggered to ensure that each 
animal had the same inter-trial interval of 10 
minutes. On day 2 (D2) animals were given 
three trials in which the platform was hidden 
beneath the surface of the water (T1-T3), fol-
lowed by a probe trial 10 minutes (T4) and 24 
hours (D3) after the final hidden platform trial. 
The platform was placed in two locations and 
animals were randomly assigned to one or other 
location, whereupon the platform remained in 
the chosen position throughout all trials. Ani-
mals were randomly delivered to the east and 
west quadrants, the target quadrant being des-
ignated as either northwest or southeast. The 
start points immediately adjacent to the plat-
form were not used (i.e. north and west, or 
south and east, depending upon target quad-
rant). High contrast external visual cues were 
placed on the walls in the room. The data from 
each drug treatment group was individually as-
sessed using repeated measures 1-way ANOVA, 
with D1V4 and D2T1 as the repeated measures, 
and Newman-Keuls multiple comparisons post-
hoc test. 
 
T-maze: At 6 months and 1 week after the com-
mencement of drug administration, spatial-
working memory was assessed using the T-
maze spontaneous alternation test [49]. The T-
maze comprised 3 arms constructed of black 
Plexiglas each 41cm long and 6cm wide, sur-
rounded by transparent Plexiglas walls (15cm 
high). The start box (6cm x 7.5cm) was located 
at the base of the central arm. Vertical sliding 
doors gave access to/from the start box and 
each arm of the maze. 24 hours prior to each 
test day, mice were habituated to the maze dur-
ing a 10 minute period of free exploration. Dur-
ing the test day, the mice underwent 1 test ses-
sion made up of 5 trials. At the beginning of trial 
1, mice were placed in the start box with the 
door closed for 30 seconds. The door was then 
opened and the mice were free to choose either 
the left or the right arm. Once a decision was 
made (all four limbs across threshold of arm) 
the mice were left in the goal arm for 30 sec-
onds before being returned to the start box. This 
process was repeated over 5 consecutive trials 
separated by a 5 second inter-trial interval, dur-
ing which mice remained in the start box. Any 
mouse failing to complete 5 consecutive trials 
within 10 minutes was discounted from that 
test session. Alternation rate (% alternation) of 
arm choice was measured over the 5 trials on 
three consecutive testing days. The mean of the 
three testing days are presented. Alternation 
rates were analysed by 1-way ANOVA with sig-
nificance set at P<0.05. (Note there was no 
statistical significance so no post-hoc tests were 
conducted) 
 
Tissue preparation 
 
After 6 months and 2 weeks of treatment, the 
animals were anaesthetised with isoflurane and 
sacrificed by transcardial perfusion with cold 
saline. Brains were harvested and hemisected 
midsagitally. One hemisphere was snap frozen 
in liquid nitrogen for biochemical analyses, the 
other fixed in 4% paraformaldehyde for 48hours 
for histology and immunohistochemistry. From 
each mouse a kidney was also isolated and 
snap-frozen for subsequent analysis of periph-
eral ACE activity. 
 
For western blots, fresh-frozen brain tissue was 
homogenized in 10 volumes (wt:vol) of tissue 
homogenization buffer (THB; 250mM Sucrose, 
20mM Tris base, 1mM EDTA, 1mM EGTA). The 
homogenate was mixed 1:1 with 0.4% dietha-
nolamine buffer (DEA; 200ul DEA, 1ml 5M NaCl, 
ddH2O to 50ml) and centrifuged at 135,000xg 
at 4°C for 1 hour. The supernatant was saved 
as the soluble fraction. 
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For the ACE activity assay and ACE ELISA, fresh-
frozen brain and kidney were homogenised in a 
non-detergent buffer containing 50mM Tris (pH 
7.4) with 2.3mm zirconia/silica beads (Thistle 
Scientific), in an automatic homogeniser 
(Stretton Scientific) for 2 x 15 seconds at 6000 
rpm. The homogenates were then spun for 15 
minutes at 13000 rpm in a centrifuge refriger-
ated to 4°C. 
 
For immunohistochemistry the fixed brain tissue 
was sliced coronally at 3mm intervals and the 
slices embedded in paraffin wax. Sections 6μm 
in thickness were collected onto aminopropyl-
triethoxysilane-coated slides, dried on a hot-
plate and stored at room temperature until 
used. 
 
ACE activity assay 
 
ACE activity in mouse brain and kidney tissue 
was determined as described previously [45], by 
use of a fluorogenic substrate for angiotensin 
converting enzyme (Abz-FRK(Dnp)-P) (Biomol), 
prepared according to manufacturer's instruc-
tions. The protein concentration in the homoge-
nates was measured using the total protein kit 
(Sigma-Aldrich). Samples containing 50µg of 
protein were diluted in HEPES buffer (595mg in 
50ml dH2O, pH 6.5) and 50µl aliquots of each 
diluted sample were incubated in triplicate for 
18 hours at 26°C with Abz-FRK(Dnp)-P. Further 
triplicate aliquots of each sample were incu-
bated with 10µg of 100mM captopril (Biomol) to 
inhibit the reaction. The fluorescence of Abz-
FRK(Dnp)-P was measured in a 96-well plate 
using a FLUOstar OPTIMA plate reader, and the 
difference in fluorescence between captopril-
inhibited and non-inhibited samples used to 
calculate ACE activity (expressed in arbitrary 
units). Treatment groups were compared by 1-
way ANOVA, with Dunn’s multiple comparison 
post-hoc test where appropriate, with signifi-
cance set at P<0.05. 
 
Mouse ACE protein ELISAs 
 
Homogenates were prepared and, after total 
protein levels were measured as described 
above, stored at -80°C until used. A commer-
cially available sandwich ELISA (R&D systems) 
was used on duplicate samples of mouse brain 
homogenate, 25µg total protein/ml diluted in 
100µl of 1% PBS/BSA. Rat-anti mouse ACE 
(4µg/ml working concentration) was coated 
overnight on Costar EIA microplates, washed 
five times with PBS/0.05% tween 20 and 
blocked with 1% PBS/bovine serum albumin 
(BSA) (1%PBS/BSA) for 2 hours. After a further 
five washes, samples and recombinant human 
ACE standards (R&D Systems) were added to 
the plate for 2 hours with shaking. After 2 hours 
the plates were washed and incubated with 
biotinylated goat anti-mouse ACE antibody 
(400ng/ml working concentration) for 2 hours. 
After further washing of the plates, streptavidin 
HRP (1:200) was added for twenty minutes in 
the dark, followed by tetramethylbenzidine 
(TMB) which was left in the dark for 30 minutes. 
The reaction was stopped with 2N sulfuric acid 
and the emission read at 450nm. ACE concen-
trations were determined by interpolation from 
standard curves determined for each plate by 
simultaneous assay of recombinant human ACE 
diluted to a range of known concentrations. 
Data were analysed by 1-way ANOVA with 
Dunn’s multiple comparison post-hoc test, with 
significance set at p<0.05. 
 
Immunohistochemistry 
 
Glass microscope slides (3 x 1 inch, CellPath) 
were prepared by soaking in 10% Decon deter-
gent (Fisher Scientific) overnight, then washed 
in running hot water for 1 hour and rinsed with 
distilled water before being left to dry in a 60°C 
oven overnight. Slides were then sequentially 
dipped for 15 second intervals in 2% aminopro-
pyltriethoxysilane in ethanol, then ethanol and 
lastly distilled water. They were dried overnight 
at 37°C and stored in boxes at room tempera-
ture until use. 
 
Sections were dewaxed in Clearene, dehydrated 
in 100% ethanol and immersed in 3% hydrogen 
peroxide in methanol for 30 minutes to block 
endogenous peroxidase activity. Non-specific 
binding was blocked by incubation with M.O.M 
mouse Ig blocking reagent (Vector M.O.M immu-
nodetection kit, Vector Laboratories). Sections 
were washed in PBS and incubated for 5 min-
utes in a working solution of M.O.M diluent. Ex-
cess M.O.M diluent was tipped off the sections 
and the primary antibody added and left over-
night. The sections were then washed with PBS 
and M.O.M biotinylated anti-mouse IgG reagent 
was added for 10 minutes. Sections were rinsed 
in PBS and incubated for 5 minutes with Vec-
tastain Elite ABC reagent. Sections were again 
washed in PBS and then incubated with DAB 
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(Vector Laboratories) for 7 minutes. After incu-
bation with DAB, sections were washed in water 
and immersed in copper sulphate DAB enhan-
cer for 4 minutes, counterstained with haema-
toxylin, dehydrated, cleared and mounted in 
Clearium. 
 
The primary (murine) antibodies used were 4G8 
(directed at Aβ17-24; Millipore, MAB1561) and 
AT8 (directed at phospho-tau; Autogen Bioclear, 
BR03). 4G8 labelling required a 20 minute pre-
treatment of sections with formic acid and was 
applied overnight at 1:16000. AT8 was applied 
overnight at 1:3000 without pre-treatment. Both 
were used at room temperature. 
 
The immunohistochemically stained sections 
were examined under x10 and x20 objectives. 
Labelling of intraneuronal Aβ was scored in 
whole sections as 0 (absent), 1 (sparse) or 2 
(abundant). Aβ plaques were scored as 0 
(absent), 1 (few), 2 (moderate) and 3 
(extensive). Vascular Aβ was scored as 0 
(absent) or 1 (present), while phospho-tau posi-
tive neurons were scored 0 (none), 1 (few), 2 
(moderate) and 3 (severe). Approximately 10% 
of sections were re-scored at a later date to 
check for consistency. Data were analysed us-
ing Kruskal-Wallis test for non-parametric data, 
with Dunn’s multiple comparison post-hoc test. 
 
Quantification of full length APP 
 
Soluble proteins were isolated from brain tissue 
as described and the levels of APP measured. 
10µg of soluble protein was loaded onto a Tris-
bis 4-12% polyacrylamide gel and the proteins 
separated by electrophoresis at 150V for 1.5 
hours. Samples from each treatment group 
were randomly loaded onto one of 3 gels run 
concurrently, with a single control sample 
loaded onto all three gels as a reference sam-
ple. Proteins were transferred to a PVDF mem-
brane and probed with MAB348 (Millipore) to 
detect full length APP, and with GAPDH antibody 
(Sigma-Aldrich) to assess equivalent loading. 
Bands were visualised using the appropriate 
Odyssey Infrared secondary antibodies (IRDye, 
LiCor) and scanned by Odyssey Infrared Imaging 
System (LiCor). The relative intensity of each 
band was normalised to the mean of the 3 ref-
erence sample intensities. Data were analysed 
by 1-way ANOVA and Newman-Keuls Multiple 
Comparison post-hoc test, with significance set 
at P<0.05. 
Results 
 
Mean arterial blood pressure (MABP) 
 
Preliminary analysis of baseline mean arterial 
blood pressure (MABP) demonstrated that there 
were no significant differences in MABP be-
tween the three groups prior to any drug treat-
ment. Thereafter 1-way ANOVA revealed signifi-
cant reductions in MABP in the captopril group 
2 weeks after treatment commenced, which 
persisted until the 6 month time point (p<0.05). 
In the eprosartan group, MABP was significantly 
reduced 3 months after treatment commenced 
(p<0.001); however, by 6 months MABP had 
returned to baseline. In the control group there 
was a significant increase in blood pressure by 
6 months, most likely an effect of normal ageing 
(p<0.01) (Figure 1). 
 
Behaviour – Morris water maze 
 
Aged 3xTGAD in all three treatment groups per-
formed well in the visible trials, significantly re-
ducing their escape latency by D1V4 compared 
with D1V1 (p<0.05) (Figure 2A and 2B). How-
ever, when the first hidden platform trial was 
conducted 24 h after the last visible platform 
trial, all 3 treatment groups demonstrated sig-
nificant spatial memory deficits regardless of 
drug treatment (Figure 2A and 2C), A repeated 
measures 1-way ANOVA (with escape latencies 
on D1V4 and D2T1 as the repeated measures), 
showed escape latencies to be significantly 
longer in all three groups on D2T1 than on 
D1V4 (p<0.05, Figure 2A and 2C). Similarly, 
short-term memory was detrimentally affected 
in all three groups, as the escape latency did 
not significantly improve between D2T1 and 
D2T3, despite a relatively short inter-trial inter-
val of 10 minutes (Figure 2A). In addition, the 
difference between each groups performance 
on the first trial of day 2 and the last trial of day 
1 was generated (D2T1-D1V4; Figure 2C); the 
large number generated in all three groups is 
indicative of a poor performance in this test. 
 
T-maze 
 
The arm choice over the 5 consecutive tasks 
was recorded for each animal, and alternation 
rate was calculated from the percentage of cor-
rect arm choices (alternation between left and 
right). Drug treatment did not affect perform-
ance in the spontaneous alternation task as 1-
Angiotensin II-inhibition and AD 
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way ANOVA revealed no significant differences 
in performance between the three groups 
(Figure 3). Alternation reflects an animals’ moti-
vation to explore its environment and typical 
alternation rates are around 75%. Neither the 
two treatment groups, nor the control group, 
achieved an alternation rate greater than 65% 
throughout the testing period (data not shown).  
 
ACE activity 
 
Measures of central and peripheral ACE activity 
were assessed in homogenates of brain and 
kidney respectively in all groups (Figure 4). In 
keeping with our previous work which involved 
young animals of the same strain [45], ACE ac-
tivity tended to be higher in brain than kidney. A 
significant reduction in ACE activity was ob-
served in the captopril group, in all other groups 
no significant effect of drug treatment was de-
tected in either brain or kidney. 
 
ACE ELISA 
 
As the activity of ACE does not always mirror its 
level in brain and CSF in humans [50] we meas-
ured ACE concentration as well as activity, to 
assess the relationship between the two in 
these transgenic mice (Figure 5). ACE concen-
tration differed significantly between the ep-
rosartan, captopril and control groups (p=0.03); 
on post hoc analysis with Dunn’s test, only 
measurements in eprosartan- and captopril-
treated mice differed significantly (p<0.05), the 
concentration of ACE being lower in mice given 
eprosartan. 
 
Immunohistochemistry 
 
Both intraneuronal Aβ and Aβ plaques were de-
tected in the hippocampus in all groups (Figure 
6A and 6B). Grading of plaque load revealed 
modest variation between the groups: captopril-
treated mice tended to have higher mean 
plaque scores but Kruskal-Wallis test revealed 
that the differences were not significant (Figure 
6A). Little variation between groups was seen in 
the level of intraneuronal Aβ (Figure 6B) or the 
neuronal phospho-tau (Figure 6C). Accumula-
tion of cerebrovascular Aβ was observed in all 
three groups; the captopril group had less than 
the other groups but the difference was not sta-
tistically significant (Figure 6D). 
 
APP levels 
 
The level of full-length APP did not differ signifi-
cantly between the drug-treated mice and con-
trols (Figure 7).  
 
Discussion 
 
We previously demonstrated a lack of effect on 
neuronal or total oligomeric Aβ or extracellular 
Figure 1. Mean Arterial Blood Pressure (MABP): data represent mean ± sem of MABP measured in control, captopril 
and eprosartan treated animals at baseline and at 2 weeks, 3 and 6 months of treatment. Preliminary analysis with 1
-way ANOVA and Dunns multiple comparison post-hoc test demonstrated that there were no significant differences 
between the groups at baseline. Data within each treatment group were analysed using repeated measures 1-way 
ANOVA, with Newman-Keuls multiple comparisons post-hoc test. * indicates significantly different from baseline 
(p<0.05, **p<0.01, ***p<0.001) 
Angiotensin II-inhibition and AD 
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Aβ pathology following short-term (2-month) 
treatment of younger 3xTGAD mice (aged 5-6 
months) with either the ACE-I captopril or the 
ARBs eprosartan and valsartan [45]. In the pre-
sent study we have examined whether a longer 
period of treatment (for 6 months) extending 
Figure 2. Aged 3xTGAD mice have spatial memory deficits in the 2-day water maze protocol, irrespective of drug treat-
ment. Performance in the visible platform trials (D1V1-D1V4), hidden platform trials (D2T1-D2T3) and the probe trial 
(D3) are shown in (A, B) and spatial memory in the water maze is assessed as absolute escape latency (A, C) or as 
the latency difference (D; D2T1-D1V4), where D2T1 was performed 24 hours after D1V4. Data from each treatment 
group were analysed by repeated measures 1-way ANOVA, with Newman-Keuls multiple comparison post-hoc test. * 
indicates significantly different from the escape latency on D1V4 in all three treatment groups, (*p<0.05, **p<0.01, 
***p<0.001. None of the treatment groups achieved an escape latency greater than chance on any of the hidden 
trials, nor on the probe trial (D3). 
Figure 3. Drug treatment did not affect performance of 
aged 3xTGAD mice in the spotaneous alternation t-maze 
protocol. Data were analysed by 1-way ANOVA with signifi-
cance set at p<0.05. 
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into older age affects the clinical or pathological 
development of Aβ and tau pathology in 3xTGAD 
mice. Since our previous study showed no dif-
ferences between eprosartan and valsartan, 
and preliminary findings from the Observational 
Study on Cognitive function and systolic blood 
pressure Reduction (OSCAR) trial [51] showed 
eprosartan to improve cognitive performance 
whilst lowering blood pressure [52], we elected 
to concentrate on eprosartan 
for the longer-treatment study. 
 
Present findings in relation to 
previous research 
 
Consistent with expectations 
for this transgenic model [46], 
intraneuronal Aβ, extracellular 
Aβ plaques, vessel-associated 
Aβ and neuronal phospho-tau 
were detected in all 3 groups 
of mice at 16 months of age, 
enabling assessment of the 
effect of anti-hypertensives on 
the development of these pa-
thologies. In keeping with our 
data from younger animals 
[45], we found little evidence 
that 6 months of treatment 
with either captopril or ep-
rosartan influenced the level 
of intraneuronal Aβ, extracellu-
lar Aβ, vascular Aβ or neuronal phospho-tau. 
Although captopril treated mice tended to have 
higher mean plaque scores and lower cere-
brovascular Aβ (in keeping with the suggestion 
that ACE can degrade Aβ), neither of these dif-
ferences were statistically significant. 
Drug dose and blood pressure 
 
In our previous study in a younger cohort of 
3xTGAD mice, captopril at a dose of 5g/l pro-
duced an unexpected but significant progres-
sive and sustained reduction in MABP. To try to 
reduce the potential influence of the hypoten-
sive actions of captopril in the older mice and to 
make our study more comparable to that of 
Hemming et al. [53] we reduced the captopril 
dose to 2g/l in the present study. Even the 
lower dose, the same as that used by Hemming 
and colleagues [53], produced a reduction in 
MABP at 2 weeks that was sustained at 3 
months. However, by 6 months MABP had re-
verted to baseline level. We cannot compare our 
observations with those of Hemming and col-
leagues as they did not record MABP in their 
mice.  
 
In eprosartan-treated mice a similar reduction in 
MABP was observed at 3 months but which was 
no longer present at 6 months. Whilst we used 
doses that would be expected to have minimal, 
if any impact on MABP, the fact that reductions 
were observed (as in our previous study) sug-
Figure 4. Effects of ACE-inhibitor and ARB treatment upon ACE activity in 
the aged 3xTGAD mouse. ACE activity is expressed in arbitratry units and 
data presented represent mean ± SEM. 1-way ANOVA with Dunn's multiple 
comparison post-hoc test revealed no significant differences in ACE activity 
between the three treatment groups in brain tissue. In kidney tissue there 
was a significant reduction in ACE activity in the captopril treated group. 
ACE-activity tended to be lower in kidney tissue than in brain in all three 
treatment groups. 
 
Figure 5. ACE-inhibitor and ARB treatment does not 
affect ACE protein levels in the aged 3xTGAD mouse. 
ACE protein level was assesed by ELISA and data 
represent mean pg/ml ± SEM. 1-way ANOVA with 
Dunn's post-test for multiple comparisons revealed 
no significant differences between control and the 
two drug-treatment groups, however ACE protein was 
significantly lower in the eprosartan group compared 
with captopril (p <0.05). 
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gests that the 3xTGAD may be particularly sus-
ceptible to changes in MABP. The subsequent 
recovery in MABP over the treatment period 
may reflect changes to physiological processes 
that regulate blood pressure; this has been re-
ported in transgenic models of AD [54]. It is un-
Figure 6. Chronic ACE-inhibitor or ARB treatment does not affect the development of amyloid plaques (A, subiculum 
shown), intraneuronal amyloid (B, hippocampus shown), neuronal phospho-tau (C) or vessel amyloid (D) in aged 
3xTGADmice. Images were analysed using a scoring system (see methods for details). Data were analysed by Kruskal
-Wallis test with Dunn's multiple comparison post-hoc test where appropriate and significance set at p<0.05. Data 
presented are median values with representative images from each staining process illustrated at x20 magnification. 
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clear whether a similar phenomenon occurs in 
AD patients, although reductions in blood pres-
sure have been observed both before and after 
the development of AD [55, 56]. The changes 
may also be a function of the advancing age of 
the animals since control untreated mice dem-
onstrated a significant rise in blood pressure by 
6 months. 
 
It is possible that any positive cognitive effects 
of these drugs could have been masked by ef-
fects of hypotension the drugs produced. Non-
hypotensive doses of the ARB telmisartan im-
proved cognitive function and white matter 
changes in hypoperfused mice but these posi-
tive outcomes were lost at a hypotensive dose 
of the drug [57]. Another ARB, losartan, was 
associated with reduced Aβ plaques in a trans-
genic mouse at a dose considerably below the 
blood pressure-lowering threshold [34]. Like-
wise olmesartan in low-doses, but not in a high-
dose, which induced hypotension improved cog-
nitive function in another experimental model 
[44]. These results suggest that there may be a 
fine balance between a dose of ARBs that bene-
fits cognitive function and a dose that produces 
hypotension. 
Effects upon cognitive function 
 
Several groups have demonstrated an improve-
ment in cognitive function in rodent and mouse 
models of AD following ACE-I or ARB (including 
olmesartan) treatment, sometimes with and 
sometimes without changes in Aβ pathology 
[34, 35, 43, 44, 58-60]. However, in the pre-
sent study, no improvement was observed in 
cognitive function in either of the two drug-
treatment groups, with the data demonstrating 
no effects upon long-term memory or spatial-
working memory as tested in a 2 day Morris 
Water Maze paradigm. Although this task was 
previously shown to be sufficiently sensitive to 
detect impairment in longer-term memory in 
3xTGAD as compared to wild-type mice, other 
watermaze paradigms may be more sensitive to 
detect subtle alterations in serial spatial mem-
ory [61, 62] 
 
A T-maze task for assessment of spontaneous 
alternation behaviour was previously used to 
demonstrate restoration of cognitive function in 
Aβ25-35-injected mice by the centrally-acting ACE-
inhibitor, perindopril [58]. Captopril is also re-
ported to be centrally-active and was found to 
slow cognitive decline in hypertensive patients 
[12] and to have protective effect along with 
perindopril in slowing cognitive decline in AD 
[12]. Typical alternation rates for the spontane-
ous alternation test are around 75% [63]. How-
ever, the rates were lower than expected in all 
three groups in the present study: 61% 
(untreated control), 66% (captopril) and 58% 
(eprosartan). These lower than normal levels of 
alternation across all groups may indicate a 
reduction in exploratory drive [64] – perhaps a 
consequence of age or genotype. 
 
ACE activity and ACE protein level 
 
In keeping with our previous work [45], ACE ac-
tivity was broadly comparable in brain and kid-
ney in this study, although activity in the kidney 
tended to be slightly lower. In the captopril 
treated group activity in the kidney was signifi-
cantly lower than that in brain, possibly because 
captopril is more potent in the periphery than 
the brain or that captopril is not as centrally 
active as is suggested in other studies. In com-
parison to our previous study in younger ani-
mals from the same transgenic line, ACE activity 
in both brain and kidney was somewhat lower, 
which may be an effect of age. Age-related re-
Figure 7. ACE inhibitor and ARB treatment does not 
affect expression of full length amyloid precursor 
protein (APP) in the aged 3xTGAD mouse. Full length 
APP was assessed by western blot in the soluble pro-
tein fraction extracted from fresh-frozen brain tissue. 
Samples from each treatment group were randomly 
loaded onto one of 3 gels run concurrently, with a 
single control sample loaded onto all three gels as a 
reference sample. The relative intensity of each band 
was normalised to the mean of the 3 reference sam-
ple intensities. Data were analysed by 1-way ANOVA 
with significance set at P<0.05. 
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duction in serum ACE activity was previously 
reported in Fischer 344 rats [65]. In contrast, 
ACE activity is significantly elevated in human 
post-mortem brain tissue [50, 66]. There was 
no significant difference in ACE protein level 
between the three animal groups; however a 
modest reduction in ACE concentration in the 
eprosartan group which coincided with a mod-
est increase in the captopril-treated group re-
sulted in a significant difference between these 
two groups. It is not clear why these opposing 
effects occurred. The different mechanisms of 
actions of the drugs may induce different feed-
back responses. 
 
Limitations of the study 
 
Despite our use of a lower dose of captopril to 
that used in our previous study [45] and its se-
lection based on use by other groups [53], the 
older 3xTGAD mice still experienced reductions 
in blood pressure. Similarly, the dose of eprosar-
tan used, which was well tolerated in younger 
mice with no hypotensive effects, also produced 
a reduction in blood pressure at 3 months of 
treatment. These effects reduce our ability to 
isolate any potential non-vascular benefits of 
these drugs from any blood pressure-related 
changes. A limitation of our earlier study [45] 
was a lack of assessment of cognitive function. 
Here we have included 2 behavioural tests, but 
the study design may have benefited from hav-
ing a further untreated group of younger 
3xTGAD mice, to clarify if these mice have a 
normal capacity to learn the procedures or more 
sensitive measures of spatial learning and 
memory in mice. 
 
Implications and conclusions 
 
Our results suggest that prolonged treatment 
with captopril or eprosartan does not affect ac-
cumulation of Aβ or neurofibrillary pathology in 
the brains of aged 3xTGAD mice. This is in keep-
ing with some studies but not others in which 
various ACE-Is and ARBs have been shown to 
benefit cognitive function and Aβ pathology in 
animal models of AD. Similarly in humans there 
have been conflicting findings. ARBs appear to 
outperform ACE-Is in terms of having risk-
reducing effects in AD [8, 9]. When ACE-Is are 
sub-divided according to their blood brain bar-
rier-penetrating or chemical properties there 
appear to be differential effects on risk and pro-
gression in AD [23] and in the risk of incident 
mild cognitive impairment [17]. Although we 
observed a significant reduction in ACE activity 
in the periphery of the captopril-treated group, 
we found a surprising lack of inhibition of cen-
tral ACE activity which is difficult to explain. The 
differences in outcome between current and 
previous studies most likely relate to the differ-
ent mouse strains used as well as factors relat-
ing to the mechanisms of action of individual 
drugs; there is ongoing debate as to whether 
the different ACE-Is [67] or ARBs [68] are truly 
interchangeable from a functional perspective. 
Overall the current findings suggest that ACE-Is 
(and ARBs) do not have a major effect on the 
development and progression of Aβ pathology in 
this mouse model of AD, and that any potential 
benefit of these drugs for the treatment of AD 
may be critically influenced by the dose admin-
istered and the extent to which it reduces blood 
pressure. 
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